STOCK TITAN

Paratek Pharmace - PRTK STOCK NEWS

Welcome to our dedicated page for Paratek Pharmace news (Ticker: PRTK), a resource for investors and traders seeking the latest updates and insights on Paratek Pharmace stock.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical innovator developing advanced therapies for complex infectious diseases. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical research, and strategic initiatives driving antibiotic development.

Key resources include: NUZYRA® treatment advancements, partnership announcements with global health organizations, and progress in addressing antimicrobial resistance. Track updates on pulmonary anthrax preparedness programs and international expansion efforts through our verified news collection.

Discover official communications about Paratek's pipeline developments, including non-tuberculous mycobacterial disease research and antibiotic stewardship programs. All content is sourced from regulatory filings and verified news outlets to ensure reliability for investment analysis and medical research.

Bookmark this page for streamlined access to Paratek's latest achievements in combating life-threatening infections through innovative tetracycline-derived therapies. Check regularly for updates on FDA interactions, European market authorizations, and clinical trial outcomes.

Rhea-AI Summary
Paratek Pharmaceuticals announces new data presentations at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Gurnet Point Capital and Novo Holdings complete acquisition of Paratek Pharmaceuticals for $462 million, including assumption of debt. Stockholders to receive $2.15 per share in cash and $0.85 per share as Contingent Value Right upon achieving $320 million in U.S. NUZYRA net sales by 2026. Paratek to be delisted from NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Paratek Pharmaceuticals announces stockholders' approval of merger agreement proposal
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) reported $33.8 million in NUZYRA net U.S. sales, a 35% increase from Q2 2022, and announced an acquisition agreement with Gurnet Point Capital and Novo Holdings A/S. The company also highlighted a BARDA contract modification and a positive opinion for orphan medicinal product designation for NUZYRA for the treatment of NTM lung disease in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Paratek Pharmaceuticals announced that it has filed definitive proxy materials and a letter to stockholders in connection with its acquisition by Gurnet Point Capital and Novo Holdings. Stockholders will receive an upfront cash payment of $2.15 per share and a contingent value right of $0.85 per share upon the achievement of a commercial milestone, resulting in a total potential value of $3.00 per share. The special meeting of stockholders will be held on September 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
NexPoint Event Driven Fund demands access to all records to investigate potential breach of fiduciary duty by Paratek Pharmaceuticals' board of directors in relation to the proposed acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
Paratek Pharmaceuticals announces modification to its Project BioShield contract with BARDA for the development of NUZYRA anthrax treatment. The next procurement will be split into two based on specific development milestones. Positive top-line data expected in Q1 2024 and Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
Paratek Pharmace

Nasdaq:PRTK

PRTK Rankings

PRTK Stock Data

127.83M
45.60M
11.7%
55.08%
4.6%
Biotechnology
Healthcare
Link
United States
Boston